-
公开(公告)号：CA2697583A1
公开(公告)日：2009-04-02
申请号：CA2697583
申请日：2008-09-26
Applicant: PORTOLA PHARM INC
Inventor： LU GENMIN , PHILLIPS DAVID R , ANDRE PATRICK , SINHA UMA
IPC: C12N9/64 , A61K31/4545 , A61K31/5377 , A61K31/715 , A61K31/727 , A61K38/36 , A61K38/48 , A61K39/00 , A61K39/395 , A61K47/48 , A61P7/02 , A61P7/04 , C07H21/00 , C07K14/00 , C07K16/00 , C12N5/10 , C12P21/00
Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
-
公开(公告)号：CA2688319A1
公开(公告)日：2008-11-13
申请号：CA2688319
申请日：2008-05-02
Applicant: PORTOLA PHARM INC
Inventor： GAO DACAO , ANDRE PATRICK , PHILLIPS DAVID R , STEPHENS GILLIAN
Abstract: The present invention provides new methods of treating thrombosis and car diovascular diseases using of antithrombotic agents, as well as methods of d etermining therapeutically effective amounts of antithrombotic agents and un it dose formulations thereof.
-
公开(公告)号：CA2688317A1
公开(公告)日：2008-11-13
申请号：CA2688317
申请日：2008-05-02
Applicant: PORTOLA PHARM INC
Inventor： ANDRE PATRICK , PHILLIPS DAVID R , HOMCY CHARLES J
IPC: A61K31/4365 , A61K31/34 , A61K31/352 , A61K31/405 , A61K31/421 , A61K31/4406 , A61K31/616 , A61P7/02 , A61P9/00 , C12N9/02 , C12Q1/00
Abstract: The present invention provides methods and compositions useful in the tre atment or prevention of cardiovascular disorders in individuals for whom the rapy with a COX-1 enzyme inhibitor is not feasible due to sensitivity, intol erance, or resistance to the inhibitor. Additionally, the invention provides methods of treating cardiovascular disorders in an individual who is receiv ing a therapeutically effective dose of a TP modulator and is instructed or advised to avoid and/or not to take aspirin or another COX-1 inhibitor.
-
公开(公告)号：CA2684722A1
公开(公告)日：2008-11-13
申请号：CA2684722
申请日：2008-05-02
Applicant: PORTOLA PHARM INC
Inventor： ANDRE PATRICK , CONLEY PAMELA B , SINHA UMA
IPC: A61K31/235 , A61K31/422 , A61K31/435 , A61K31/517 , A61K45/06 , A61P7/00 , A61P7/02 , A61P9/00
Abstract: The present invention is directed to pharmaceutical compositions and meth ods of using combination therapies containing [4 (6-fluoro-7-methylamino-2,4 -dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfon ylurea, or a pharmaceutically acceptable salt thereof, for the treatment of thrombosis diseases.
-
公开(公告)号：AU2005235289A1
公开(公告)日：2005-11-03
申请号：AU2005235289
申请日：2005-04-18
Applicant: PORTOLA PHARM INC
Inventor： ANDRE PATRICK , HOMCY CHARLES , PHILLIPS DAVID R
IPC: A61K31/4745 , A61F2/02 , A61K31/473 , A61K31/52
Abstract: The present invention provides novel compositions and methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient undergoing a vascular intervention. More particularly, the present invention provides intravascular devices coated with one or more spleen tyrosine kinase (Syk) inhibitors. Methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient by treatment with such intravascular devices are also provided. In addition, the present invention provides methods for treating sickle cell disease using Syk inhibitors.
-
Patent Agency Ranking
公开(公告)号：HUE050063T2
公开(公告)日：2020-11-30
申请号：HUE16167534
申请日：2008-09-26
Applicant: PORTOLA PHARM INC
Inventor： LU GENMIN , PHILLIPS DAVID R , ANDRE PATRICK , SINHA UMA
-
公开(公告)号：LT3078743T
公开(公告)日：2020-09-25
申请号：LT16167534
申请日：2008-09-26
Applicant: PORTOLA PHARM INC
Inventor： LU GENMIN , PHILLIPS DAVID R , ANDRE PATRICK , SINHA UMA
-
公开(公告)号：AU2019204123A1
公开(公告)日：2019-07-04
申请号：AU2019204123
申请日：2019-06-13
Applicant: PORTOLA PHARM INC
Inventor： LU GENMIN , PHILLIPS DAVID R , ANDRE PATRICK , SINHA UMA
IPC: A61P7/02 , A61K31/4545 , A61K31/5377 , A61K31/715 , A61K31/727 , A61K38/36 , A61K38/48 , A61K39/00 , A61K39/395 , A61P7/04 , C07H21/00 , C07K14/00 , C07K16/00 , C12N5/10 , C12N9/64 , C12P21/00
Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or 5 have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
-
公开(公告)号：HUE031647T2
公开(公告)日：2017-07-28
申请号：HUE08834136
申请日：2008-09-26
Applicant: PORTOLA PHARM INC
Inventor： LU GENMIN , PHILLIPS DAVID R , ANDRE PATRICK , SINHA UMA
-
公开(公告)号：CY1118482T1
公开(公告)日：2017-07-12
申请号：CY161101020
申请日：2016-10-12
Applicant: PORTOLA PHARM INC
Inventor： LU GENMIN , PHILLIPS DAVID R , ANDRE PATRICK , SINHA UMA
Abstract: Ηπαρούσαεφεύρεσησχετίζεταιμεαντίδοτααντιπηκτικήςαγωγήςπουστοχεύειστονπαράγοντα Xa. Τααντίδοταείναιπρωτεϊνικάπαράγωγατουπαράγοντα Xa πουπροσδένονταιστουςαναστολείςτουπαράγοντα Xa καιέτσιτουςεξουδετερώνουνουσιαστικάαλλάδενσυναθροίζονταισεσύμπλοκοπροθρομβινάσης. Ταπαράγωγαπουπεριγράφονταιεδώστερούνταιή έχουνμειωμένηεσωτερικήαντιπηκτικήδραστηριότητα. Στοπαρόναποκαλύπτονταιμέθοδοιγιατηδιακοπήή παρεμπόδισητηςαιμορραγίαςσεένανασθενήο οποίοςβρίσκεταιεπίτουπαρόντοςσεθεραπευτικήαντιπηκτικήαγωγήμεαναστολέατουπαράγοντα Xa.
-
-
-
-
-
-
-
-
-
Search Results
70
records
(took 0.023 seconds)
